Moreover, it was shown for ovarian cancer that low dose metformin, a first line drug for treating diabetes, can also reduce the expression of EMT-associated makers, such as Twist, suggesting further options for potentially targeting this CTC-population [57]. This evidence concerns the gene TWIST1 and diabetes mellitus.